Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update

Contributed by: PR Newswire

Tags

ONCOINVENT-Q1-2025

More Like This

Oncoinvent ASA: Invitation to Result Presentation Q4 2024

Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients

Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression

Oncoinvent ASA announces oversubscribed private placement

Invitation to Immunovia's Q1 presentation

Invitation to Immunovia's Q2 presentation

Invitation to Immunovia's Q3 presentation

Invitation to Immunovia's Q4 presentation